Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Soumon Rudra et al.|Clinical Cancer Research|2024Cited by 10
Supplementary Table S1 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0
Data from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0
Supplementary Table S2 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0
Supplementary Table S3 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker AnalysisNabil F. Saba, Christine H. Chung, Ritu Chaudhary et al.|Unknown|2024Cited by 0